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A B S T R A C T
The delivery of biopharmaceuticals to the oral mucosa offers a range of potential applications including anti-
microbial peptides to treat resistant infections, growth factors for tissue regeneration, or as an alternative to
injections for systemic delivery. Existing formulations targeting this site are typically non-specific and provide
little control over dose. To address this, an electrospun dual-layer mucoadhesive patch was investigated for
protein delivery to the oral mucosa. Lysozyme was used as a model antimicrobial protein and incorporated into
poly(vinylpyrrolidone)/Eudragit RS100 polymer nanofibers using electrospinning from an ethanol/water mix-
ture. The resulting fibrous membranes released the protein at a clinically desirable rate, reaching 90 ± 13%
cumulative release after 2 h. Dual fluorescent fibre labelling and confocal microscopy demonstrated the
homogeneity of lysozyme and polymer distribution. High encapsulation efficiency and preservation of enzyme
activity were achieved (93.4 ± 7.0% and 96.1 ± 3.3% respectively). The released lysozyme inhibited the
growth of the oral bacterium Streptococcus ratti, providing further evidence of retention of biological activity and
illustrating a potential application for treating and preventing oral infections. An additional protective poly
(caprolactone) backing layer was introduced to promote unidirectional delivery, without loss of enzyme activity,
and the resulting dual-layer patches displayed long residence times using an in vitro test, showing that the
adhesive properties were maintained. This study demonstrates that the drug delivery system has great potential
for the delivery of therapeutic proteins to the oral mucosa.
1. Introduction
Due to advances in protein synthesis in recent decades, proteins and
peptides now represent one of the fastest growing classes of pharma-
ceuticals [1]. The ability to modify the chemical structure of native
proteins allows the development of more stable analogues with high
specificity, high potency, and low toxicity, resulting in higher success
rates than traditional small molecule new chemical entities in clinical
development stages [2]. A variety of potential applications for bio-
pharmaceutical delivery to the oral mucosa have been identified. These
include antimicrobial peptides as a treatment for bacterial [3] and
fungal [4] infections, such as in periodontal disease or oral candidiasis,
with resistance to traditional antimicrobials. Topical recombinant cy-
tokines such as epidermal growth factor and basic fibroblast growth
factor have shown potential in vivo for regenerating oral wounds or
ulcers caused by oral mucositis [5,6]. Some therapeutic peptides,
including salmon calcitonin and insulin, in combination with permea-
tion enhancers, have been shown in animals or humans to permeate the
oral mucosa sufficiently to achieve therapeutic doses [7,8]. Therefore,
the oral mucosa is also of interest for systemic delivery, circumventing
proteolytic degradation in the gastrointestinal tract and offering the
potential for controlled release and needleless delivery.
A significant challenge for the delivery of proteins to the oral mu-
cosa is the lack of suitable formulations that allow specific delivery. The
most commonly used formulations targeting the oral mucosa include
mouthwashes [9], gels [10], tablets [11], and dissolvable films [12].
These drug delivery systems work well for highly permeable drugs [13]
but release of the active ingredient is often non-specific, across the
entire oral cavity rather than localised into a specific region of the oral
mucosa where the drug is required. Variations in salivary flow and
mechanical forces mean that doses are poorly defined where prolonged
contact is required. To address this, we have developed an electrospun
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mucoadhesive patch with a backing layer film to promote unidirec-
tional drug delivery [14]. The system is comprised of FDA-approved
polymers and offers several advantages over existing alternatives in-
cluding in vivo residence times of up to 2 h, high patient acceptability,
high surface area, and fast release rates [15]. This system in currently
undergoing phase 2 clinical trials for the delivery clobesasol-17-pro-
pionate to treat oral lichen planus. The patches also show early promise
for the delivery of lidocaine as a topical dental anaesthetic or analgesic
[16].
A range of proteins and peptides have previously been encapsulated
into polymer nanofibers using electrospinning [17]. However, most
examples of electrospun drug delivery systems focus on biodegradable
polyesters, which tend to require chlorinated solvents to achieve solu-
bility. This leads to concerns over protein denaturation and loss of ac-
tivity [17]. Several different approaches for incorporating proteins into
electrospun membranes have been identified, for example, surface
functionalisation by chemically bonding proteins to pre-spun fibres
[18]. However, this immobilises the protein and is therefore more re-
levant for slow release applications. Much current work focuses on
electrospinning emulsions or suspensions to allow electrospinning of
proteins and polymers with incompatible solvent requirements [19,20].
This can result in activity loss and poor encapsulation efficiency due to
the solvent phases having different conductivities and separating during
the spinning process. Two separate solutions may also be electrospun
into core-shell fibres using coaxial electrospinning with two capillary
feeding channels [21]. Proteins encapsulated in the fibre core from
aqueous solutions have been shown to maintain some or all of their
activity [22,23]. However, the outer sheath layer is likely to influence
drug release profiles and the manufacturing process is considerably
more complex. To date, there are no published studies describing the
encapsulation and release of bioactive proteins from a single-phase
organic solvent mixture using uniaxial electrospinning. Here, we report
the incorporation of lysozyme as a model protein into an electrospun
mucoadhesive patch and investigate its potential for therapeutic pro-
tein delivery. This protein delivery system is unique in that it uses a
simple uniaxial electrospinning manufacturing process to encapsulate a
biologically active protein into an insoluble drug delivery system. For
the first time, we show that proteins encapsulated in these uniaxial fi-
bres retain biological activity upon release and significantly advance
the field of electrospun-mediated protein delivery.
2. Methods
2.1. Materials
Poly(vinylpyrrolidone) (PVP; MW 2000 kDa) and Eudragit RS100
(RS100; MW 38 kDa) were kindly donated by BASF, UK and Evonik
Industries AG, Germany, respectively. Poly(caprolactone) (PCL; MW
80 kDa), dichloromethane (DCM), lysozyme from chicken egg white,
lyophilised Micrococcus lysodeikticus cells, phosphate-buffered saline
tablets, fluorescein isothiocyanate isomer I (FITC), Texas red sulfonyl
chloride, sodium bicarbonate, and sodium carbonate were purchased
from Sigma-Aldrich (Poole, UK). Ethanol and dimethylformamide
(DMF) were purchased from Fischer Scientific (Loughborough, UK).
Pierce™ BCA protein assay kit was purchased from Thermo Scientific
(Loughborough, UK). Brain heart infusion broth was purchased from
Oxoid (Basingstoke, UK).
2.2. Electrospinning system
Electrospun membranes were fabricated using a system composed
of a PHD2000 syringe pump (Havard Apparatus, Cambridge, UK) and
an Alpha IV Brandenburg power source (Brandenburg, Worthing, UK).
Plastic syringes (1 mL volume; Henke Sass Wolf, Tuttlingen, Germany)
were used to drive the solutions into a 20-gauge blunt metallic needle
(Fisnar Europe, Glasgow, UK). Electrospinning was performed at room
temperature with a potential difference of 19 kV, a flow rate of 2 mL/h,
and a flight path of 14 cm.
2.3. Preparation of polymer solutions and fabrication of bioadhesive
membranes
All electrospinning solutions contained 0.1025 ± 0.00025 g/mL
PVP and 0.1225 ± 0.0005 g/mL Eudragit RS100 (by total solvent
volume before mixing). The required amounts of PVP and RS100 were
added to ethanol or an ethanol/water mixture and mixed at room
temperature using a magnetic stirrer until dissolved. Lysozyme was
dissolved in ice cold PBS (75 mg/mL) and added to the polymer solu-
tion and stirred until uniformly distributed, contributing 3 v/v % to the
final solvent composition. Electrospinning was started within 1 min of
adding the lysozyme. Placebo solutions and membranes were prepared
using 3 v/v % distilled water instead of lysozyme in PBS.
2.4. Conductivity of polymer solutions
Electrical conductivity of the polymeric solutions was measured
using a Mettler Toledo FG3 conductivity meter (Mettler Toledo,
Schwerzenbach, Switzerland), applying a conductivity standard of 1413
μS cm−1 (Mettler Toledo).
2.5. Rheology of polymer solutions
The viscosity of the polymeric solutions was measured using an
MCR 301 rheometer (Anton Paar, Graz, Austria) with a cone-plate
measuring system CP25-4/IMG1 (25 mm diameter, 4° cone angle, and
253 μm truncation) at a constant temperature (25 ± 0.1 °C) and a
sample volume of approximately 0.4 mL. Logarithmic shear rate sweep
tests were performed with 31 points in the range of 0.1 to 100 s−1
lasting 20 s per point.
2.6. Scanning electron microscopy
Electrospun membranes were imaged using a TESCAN Vega3
scanning electron microscope (SEM; Tescan, Cambridge, UK). Samples
were sputter coated with gold and imaged using an emission current of
10 kV. All images were processed using ImageJ software tools [24].
Fibre diameters were measured by ImageJ, using randomly generated
coordinates and a superimposed grid to select fibres to measure. Three
images were analysed for each composition with at least 10 measure-
ments per image.
2.7. Degree of swelling of electrospun membranes
Pre-weighed 15 mm discs (5–14 mg) were placed in sample tubes
with 1 mL distilled water for 2 h. If intact, samples were removed, and
each side pressed against a glass surface to remove excess water before
reweighing. The percentage degree of swelling was calculated using the
formula:
−
×
(M M )
M
100s d
d
where Ms is the mass of the sample after swelling in distilled water and
Md is the dry mass of the sample before swelling.
2.8. Activity and encapsulation efficiency measurement
Electrospun membrane (9–12 mg) was prepared and immersed in
2 mL PBS for 24 h. to elute the protein. A bicinchoninic acid (BCA)
protein assay was used as directed to determine encapsulation effi-
ciencies. Absorbance was measured at 562 nm using a spectro-
photometer (Tecan, Theale, UK). The apparent mass fraction de-
termined from the protein concentrations in the samples was
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normalised against the dry mass fraction of lysozyme in the electro-
spinning solution.
Lysozyme enzyme activity in samples was measured using a pho-
tometric enzyme kinetic assay as previously described [25]. Briefly,
10 μL of membrane supernatant diluted in PBS (1:10, v/v) was added to
a clear plastic 96-well plate along with 200 μL of lyophilised Micro-
coccus lysodeikticus cells (0.4 mg/mL in PBS). The change in optical
density at 450 nm (OD450) was measured over time for 10 min. Active
lysozyme concentrations of the samples were interpolated from a
standard curve created using lysozyme standards (0, 20, 40, 60, 80, and
100 μg/mL) and normalised against the total protein concentration.
2.9. Homogeneity of lysozyme incorporation
Electrospun membranes were divided into three concentric regions:
the central circle of the membrane with one third the diameter of the
whole membrane, an intermediate ring with two thirds the diameter of
the whole membrane, and the remaining outer ring. The activity and
encapsulation efficiencies of the different regions where measured as
previously described.
2.10. Fluorescent labelling of PVP and lysozyme
To label PVP, a complex with fluorescein isothiocyanate isomer I
(FITC), as described by Aulton et al., was produced [26]. FITC in 0.1 M
pH 9.2 carbonate-bicarbonate buffer (2 mg/mL, 1 mL) was added
dropwise with vigorous stirring to PVP in the same buffer (25 mg/mL,
10 mL) in an opaque sample tube. The tube was sealed and incubated at
room temperature for 3 h. The complex was purified by adding drop-
wise with stirring to acetone (500 mL) and the precipitate collected and
washed with acetone (2 × 10 mL). Excess solvents were removed by
freeze drying.
Lysozyme was labelled with Texas red sulfonyl chloride. Texas red
sulfonyl chloride (1 mg) was added, with vigorous stirring until dis-
solved, to lysozyme in 0.1 M pH 9.2 carbonate-bicarbonate buffer
(75 mg/mL, 1 mL) in an opaque sample tube. The tube was sealed and
incubated at room temperature for 24 h and the product purified using
gel permeation chromatography with Sephadex G-25 and PBS. The
solvent was removed by freeze drying.
2.11. Fabrication and imaging of fluorescent electrospun fibres
Electrospun fibres were prepared as previously described with 97 v/
v % ethanol but using Texas red labelled lysozyme and substituting 24
w/v % of the PVP with the FITC-PVP complex where appropriate.
Samples were placed on glass slides and overlaid with glass cover slips.
Imaging was performed in dual-channel mode using a Nikon A1 laser
scanning confocal microscope with 457–514 nm argon and 561 nm
sapphire lasers. All images were processed using ImageJ software tools
[24].
2.12. Release profile
Samples of electrospun membranes (20 mg) were immersed in 4 mL
PBS and 10 μL samples taken at time intervals (0, 10, 20, 30, 60, 120,
180 min.) following vortexing for 5 s. Active lysozyme concentration
was measured as previously described. To calculate cumulative release,
the active concentration was normalised against the theoretical max-
imum concentration, assuming 100% encapsulation efficiency, release,
and activity.
2.13. Growth inhibition assay with Streptococcus ratti
Streptococcus ratti (NCTC 10920, Public Health England, Salisbury,
UK) was grown overnight in 10 mL brain heart infusion broth (BHI) at
37 °C, 5% CO2 before diluting to OD600 of 0.1 in BHI. Samples of
electrospun membrane (50 ± 0.1 mg) were immersed in 1 mL sterile
PBS for 24 h with vortexing for 30 s after immersing and before sam-
pling the eluate. Sterile PBS was used as a negative control and 0.5 mg/
mL lysozyme in PBS as a positive control. Additionally, placebo patch
samples were eluted in a stock 0.5 mg/mL lysozyme solution. A 12-well
plate was filled with BHI (0.5 mL per well) before adding eluate and
controls in triplicate (0.5 mL). Each well was inoculated with 0.1 mL
bacteria and the plate incubated at 37 °C with OD600 measured every
10 min for 15 h with shaking for 1 min before each reading.
2.14. Fabrication of hydrophobic backing layer
The hydrophobic backing layer (BL) was prepared by electrospin-
ning a PCL solution on top of the bioadhesive PVP/RS100 layer. PCL
was added to a blend of DCM and DMF (90:10 v/v %) and stirred at
room temperature until dissolved to prepare a solution of concentration
10 w/v %. To enhance the attachment between the bioadhesive and
backing layer a thermal treatment was applied by heating at 65 °C for
15 min in a dry oven.
2.15. In vitro adhesion study of dual-layer patches
The adhesive properties of electrospun membranes with backing
layers were investigated in vitro. For each composition, two discs of
1 cm diameter were cut from three membranes (n = 6) and applied to
20 μL droplets of PBS on a plastic petri dish with gentle pressure from
the index finger for 5 s. The petri dishes were filled with PBS (20 mL)
and then incubated on an orbital shaker at 250 rpm at room tempera-
ture for a total of 2 weeks. The samples were inspected daily to observe
any detachment of the backing layer.
2.16. Data analysis
All data and statistical analyses were performed using GraphPad
Prism 8.0 software (GraphPad Software, La Jolla, CA). One-way
ANOVA with post hoc Tukey tests or Welch's t-tests were used to
compare differences between groups and results considered statistically
significant if p < 0.05.
3. Results and discussion
3.1. Physical properties of solutions
The morphology of electrospun fibres is strongly influenced by
processing parameters and solution properties. Conductivity and visc-
osity measurements were used to determine how the addition of a
protein affects solution properties. A typical dose of a therapeutic
peptide is in the order of micrograms [27–29], therefore a loading of
1% lysozyme by dry mass was used to simulate a loading that may be
suitable for mucosal peptide or protein delivery. Including lysozyme in
PBS caused an increase in solution conductivity from 118.4 ± 7.2 to
168.6 ± 8.6 μS/cm (p = 0.0247) and an increase in viscosity at 5 s−1
from 1.14 ± 0.18 to 1.477 ± 0.091 Pa·s (p = 0.0369) in comparison
to the equivalent solution prepared with distilled water. The increase in
conductivity on addition of lysozyme, a cationic protein, was expected
due to increased electrolyte concentration. The increase in viscosity is
typical of a protein solution [30]. An organic solvent such as ethanol is
required for the dissolution of RS100, however ethanol can act as a
protein denaturant [31]. It was therefore hypothesised that reducing
the proportion of ethanol in the electrospinning solvent mixture would
improve protein activity. Therefore, solvent mixtures with different
proportions of ethanol were investigated. Decreasing the proportion of
ethanol in the solution and replacing with water caused a linear in-
crease in conductivity (R2 = 0.9878) reaching 504 ± 33 μS/cm at 40
v/v % ethanol (Fig. 1A). This follows a similar trend to that previously
reported for pure ethanol-water mixtures and is expected due to ethanol
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having a much lower conductivity than water [32]. Reducing the pro-
portion of ethanol from 97 to 80 v/v % reduced viscosity from
1.477 ± 0.091 to 1.103 ± 0.032 Pa·s (p = 0.0214, Fig. 1B). The
decrease in viscosity at lower ethanol concentrations is consistent with
polymers adopting a globule conformation with a smaller hydro-
dynamic volume due to poorer solvation. PVP in ethanol-water mix-
tures has previously been shown to have a reduced hydrodynamic ra-
dius at lower ethanol concentrations, suggesting a transition from
chains to less solvated globules [33]. RS100 is a less hydrophilic, water-
insoluble polymer, therefore it is also likely to be poorly solvated at
lower ethanol concentrations. All polymer solutions behaved approxi-
mately as Newtonian fluids with no clear shear thickening or thinning
trend (Fig. S1).
3.2. Fabrication and morphology of electrospun membranes
Electrospun fibres containing 1 w/v % lysozyme and made using 97,
80, 60, and 40 v/v % ethanol mixed with distilled water as solvent and
a placebo membrane manufactured with 97 v/v % ethanol without
lysozyme were analysed by scanning electron microscopy. All samples
had some merged fibres and almost no bead defects (Fig. 2). No other
defects were observed. Including lysozyme caused a decrease in dia-
meter from 2.50 ± 0.71 to 2.04 ± 0.92 μm (p = 0.0402). The re-
duced fibre diameter is consistent with the observed increase in con-
ductivity, which allows the polymer solution to hold more charge,
resulting in more efficient elongation in the electric field. There was no
significant difference in diameter between 97 and 80 v/v % ethanol,
however there was a significant decrease in fibre diameter from
2.34 ± 0.63 μm to 1.28 ± 0.41 μm (p < 0.0001) and
0.58 ± 0.13 μm (p < 0.0001) when the ethanol content was reduced
from 80 v/v % to 60 and 40 v/v % ethanol respectively. Higher solution
conductivity and lower viscosity are well known to be associated with
narrower fibres [34], therefore these measurements broadly follow the
trend expected from the solutions properties. These results also similar
to those reported by Nartetamrongsutt et al., who showed that in-
cluding ionic salts in solutions of PVP in ethanol-water mixtures re-
sulted in reduced fibre diameters and increased solution conductivity
[35]. They also found that reducing the proportion of ethanol below 50
v/v % resulted in narrower fibres and a narrower distribution of fibre
diameters along with reduced solution viscosity and increased solution
conductivity.
3.3. Swelling and integrity of electrospun membranes
To be suitable as a mucoadhesive drug delivery system, the protein-
loaded membranes must swell to promote adhesion but also remain
intact in a wet environment. Samples were placed in distilled water for
2 h and visually inspected for loss of integrity and, where possible, the
degree of swelling was measured. All samples electrospun using 40 v/v
% ethanol and one of three membranes using 60 v/v % ethanol rapidly
disintegrated into small insoluble particles when added to water. In
contrast, fibres electrospun from 97 and 80 v/v % ethanol and placebo
membranes remained intact after 2 h and did not differ significantly in
degree of swelling (Fig. 3, p = 0.4342). These data suggest that 97 or
80 v/v % ethanol are suitable solvents for this polymer system and
application. The disintegration of narrower fibres may be a result of
PVP-rich domains rapidly dissolving and creating discontinuations in
the fibres. This would be expected of narrower fibres, since the smaller
diameter would make it easier for discontinuations to form and the
higher surface area and smaller contacts between fibres facilitates the
rapid dissolution of PVP.
3.4. Effect of solvent mixture on encapsulation and activity
Lysozyme was eluted from the fibres and the amount released
measured using a protein assay and its activity assessed using an en-
zyme kinetic assay relative to freshly prepared lysozyme stock solu-
tions. Encapsulation efficiency ranged from 75 ± 10 to 98 ± 8%, and
no statistically significant difference between solvents was shown
(Fig. 4, p = 0.0750). It was initially hypothesised that reducing the
concentration of ethanol in the electrospinning solution would limit
protein denaturation, leading to higher enzyme activity. However, it
was found that enzyme activity was close to 100% (96 ± 3 to
108 ± 18%) with no difference between the solvent mixtures tested.
Placebo membranes were used as negative controls and showed ap-
parent protein loading, as measured by a BCA assay, close to zero,
0.017 ± 0.015 w/w % compared to 0.928 ± 0.070 w/w % for ly-
sozyme loaded membranes (p < 0.005). The activity of the placebo
patches was also close to zero, corresponding to an active lysozyme
loading of 0.055 ± 0.042 w/w % compared to 0.892 ± 0.049 w/w %
for lysozyme-loaded membranes (p < 0.0005). This shows that the
observed protein release and enzyme activity was not a false positive
caused by dissolved polymer. Changing the ratio of solvents did not
provide a noticeable benefit in terms of activity, therefore further ex-
periments focused on 97 v/v % ethanol as the solvent, which gave an
encapsulation efficiency of 93 ± 7% and activity of 96 ± 3%. The
high encapsulation efficiencies reported here are comparable to those
previously reported for small molecule drugs encapsulated using uni-
axial electrospinning. For example, Xie et al., reported the encapsula-
tion of paclitaxel in PLGA nanofibers with loading of around 10 w/w %
and an encapsulation efficiency over 90% [36]. There is very little
published research reporting encapsulation of active proteins using
uniaxial electrospinning of a single phase solution. Eriksen et al., in-
corporated a fluorescently-labelled antimicrobial peptide into PCL
Fig. 1. Conductivity of electrospinning so-
lutions containing lysozyme with different
mixtures of ethanol and water as solvents
and placebo (P) solutions in 97 v/v %
ethanol without lysozyme (A). Viscosity of
electrospinning solutions measured at a
shear rate of 5 s−1 (B). Data are presented
as mean ± SD, with 3 independent repeats
and analysed using one-way ANOVA with
post hoc Tukey tests. *, p < 0.05; **,
p < 0.01; ***, p < 0.001.
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fibres at a loading of approximately 0.1 w/w% using a miscible me-
thanol/chloroform solvent mixture, but were unable to confirm biolo-
gical activity [37]. Conversely, emulsion and coaxial electrospinning,
with the protein in an aqueous phase, have been frequently studied for
protein encapsulation. Due to separation of solvent phases in the Taylor
cone, emulsion electrospinning often results in low encapsulation effi-
ciencies of only a few percent for globular proteins [19], however a
higher efficiency of 87.2 ± 1.8% has been achieved for collagen-like
protein in poly(lactic-co-glycolic acid) (PLGA) fibres at a loading of 5
w/w% [20]. Ji et al., compared emulsion and coaxial electrospinning
for the encapsulation of alkaline phosphatase into PCL fibres at a
loading of 0.16 w/w% from water and 2,2,2-trifluoroethanol [23].
Coaxial electrospinning resulted in 76.2 ± 8.4% enzyme activity,
while electrospinning from an emulsion resulted in 49.3 ± 4.5% ac-
tivity. Lysozyme has also previously been encapsulated in PCL/poly
(ethylene glycol) (PEG) fibres using coaxial electrospinning at loadings
of 2–6 w/w% and shown to be active, however the activity was not
quantified [22]. The polymer/solvent system described here enables
encapsulation efficiencies and activity preservation superior to what
has been achieved previously with uniaxial single phase and emulsion
electrospinning and at least as high as that achieved with coaxial
electrospinning.
Fig. 2. Scanning electron micrographs of a placebo membrane (A) and electrospun fibres containing lysozyme manufactured using different concentrations of
ethanol, shown in bottom left as v/v% (B–E). Fibre diameter distributions (F). Data are presented as median, interquartile range, and range with 3 independently
prepared samples for each solvent mixture and 10 diameter measurements per sample and analysed using one-way ANOVA with post hoc Tukey tests. *, p < 0.05;
***, p < 0.001.
Fig. 3. Degree of swelling in water of lysozyme-containing electrospun fibres
using different ethanol concentrations and placebo membranes (P). Data are
presented as mean ± SD, with 3 independent samples and analysed using one-
way ANOVA with post hoc Tukey tests. For 60 v/v % ethanol only 2 in-
dependent measurements could be made, therefore SD was not calculated.
Fig. 4. Encapsulation efficiency and activity of lysozyme in fibres electrospun
using different mixtures of ethanol and water as solvents. Data is presented as
mean ± SD, with 3 independent samples per solvent mixture, and analysed
using one-way ANOVA with post hoc Tukey tests.
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3.5. Homogeneity of electrospun membranes
To determine the distribution of PVP and lysozyme within the fibres
a novel dual fluorescent labelling approach was used. A FITC-PVP
complex and Texas red conjugated lysozyme were added before elec-
trospinning and the resulting fibres imaged using confocal microscopy.
Singly labelled control samples showed that signals were not caused by
auto fluorescence or crosstalk between channels (Fig. S2). PVP appears
to be homogenously distributed within the fibres, with any polymer
phase separation occurring over a nanometre scale below the resolution
of the microscope (Fig. 5A). Lysozyme is fully incorporated into the
fibres and almost homogeneously distributed (Fig. 5B). Some aggrega-
tion is viably present over a microscopic scale as bright regions, how-
ever this does not appear to significantly affect its activity. To de-
termine the homogeneity of the lysozyme distribution over a
macroscopic scale, the loading and activity of different regions (centre,
intermediate, outer edge) of the membrane were compared (Fig. 5D).
The loading and activity were similar across all regions tested in-
dicating that the protein is homogeneously distributed at the macro-
scopic level.
3.6. Characterisation of release kinetics using an enzymatic assay
We previously showed that a mucoadhesive drug delivery device
with a similar polymer composition had a residence time of
96 ± 26 min when applied to the human buccal oral mucosa [15]. To
be useful as a mucosal peptide delivery system, the membranes must
release their payload over a similar timescale. To measure the release
profile, lysozyme was eluted from the fibres and the active concentra-
tion measured using enzyme kinetics for up to 3 h (Fig. 6). Lysozyme
was released rapidly with 76 ± 23% released within 30 min and
88 ± 16% within 1 h. The release then begins to plateau, reaching
90 ± 13% after 2 h. The release is likely to be facilitated by rapid
water penetration due to the dissolution of PVP and the swelling of
Fig. 5. Confocal micrographs of electrospun fibres containing FITC-PVP complex and Texas-red conjugated lysozyme to show the distribution of PVP (A, green) and
lysozyme (B, red) within the fibres and an overlay of both distributions (C). Encapsulation efficiency (EE) and activity of central, intermediate, and outer regions of
lysozyme-containing membranes electrospun from 97 v/v % ethanol (D). Data is presented as mean ± SD, with 3 independent samples for each region, and analysed
using one-way ANOVA with post hoc Tukey tests. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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RS100. The lack of sheath layer associated with coaxial electrospinning
also increases release rate by decreasing the diffusion path required for
release [38]. Proteins previously encapsulated in water-insoluble
polymer fibres have shown considerably slower release rates. Eriksen
et al., reported that an antimicrobial peptide was released linearly from
uniaxial PCL fibres, with<50% released within 2 h [37]. Ji et al.,
reported that bovine serum albumin undergoes biphasic release from
PCL fibres prepared both with emulsion and coaxial electrospinning,
with an initial burst of around 15% released within 4 h, followed by
prolonged release which begins to plateau at around 50–70% after
35 days [23]. Wei et al., showed that collagen-like protein was released
from PLGA fibres prepared by emulsion electrospinning linearly for the
first 1–2 weeks, reaching 50–70% depending on fibre diameter [20].
Although other polymer systems may be more suitable for sustained
release over a period of days, the system reported here is unique in that
it enables protein release over timescales relevant for delivery to the
oral mucosa without rapidly dissolving.
3.7. Fabrication of backing layer and effect on activity
A film of hydrophobic PCL was introduced to act as a backing layer
to promote unidirectional delivery and protect against mechanical
forces in the mouth as previously described by Colley et al., in dual-
layer patches for the unidirectional delivery of clobetasol to the oral
mucosa [14]. PCL was electrospun on top of the protein-loaded mu-
coadhesive layer and the dual-layer patch heated at 65 °C to melt the
PCL fibres into a continuous film. SEM micrographs show the fabrica-
tion of patches with a continuous backing film and that the fibrous
structure of the lower layer was preserved (Fig. 7A–B). Activity
measurements revealed that thermal treatment did not cause significant
loss of enzyme activity (p = 0.8326). Applying dry heat at 100 °C for
1 week resulted in a decrease in activity from 84 ± 4% to 30 ± 16%
(p = 0.0017), showing that lysozyme in the electrospun fibres is sus-
ceptible to heat denaturation in extreme conditions.
3.8. In vitro testing of residence time
A simple in vitro residence time test was applied to assess whether
lysozyme had a detrimental effect on patch adhesion or structural in-
tegrity. Samples were applied to a petri dish, immersed in PBS and
shaken for two weeks with daily inspection for detachment of the
backing layer. Both the lysozyme-containing patches and the placebo
patches remained attached until the end of the experiment, suggesting
that lysozyme does not disrupt membrane integrity, adhesion, or at-
tachment of the backing layer.
3.9. Lysozyme released from membranes inhibits the growth of
Streptococcus ratti
Over 600 different species of microbes reside commensally within
the oral cavity in healthy individuals [39]. Many of these organisms
have the ability to become pathogenic if the oral mucosa is wounded or
compromised, or if there is significant dysbiosis in the microbial flora.
Lysozyme is a glycoside hydrolase and acts as an antimicrobial agent by
catalysing the hydrolysis of linkages between N-acetylmuramic acid
and N-acetyl-D-glucosamine residues in peptidoglycan, the major cell
wall component of Gram-positive bacteria. We next tested if membrane-
released lysozyme was able to cleave peptidoglycan and cause bacterial
cell lysis in Streptococcus ratti, a Gram-positive oral bacterium found in
the oral cavity that has been associated with dental biofilms [40] and is
known to be affected by lysozyme activity [41]. Lysozyme was eluted
from electrospun membranes and its effects on inhibiting bacteria
growth assessed. Eluted lysozyme significantly inhibited the growth of
S. ratti by 51% after 15 h compared to eluate from a placebo membrane
control (51.1 ± 5.7 vs 0.6 ± 1.6, p < 0.0001, Fig. 8). These data
clearly show that lysozyme released by electrospun membranes retains
its biological activity and is able to inhibit bacterial growth and indicate
that these membranes may be effective at treating oral bacterial in-
fections or as covering for oral wounds or lesions that may be suscep-
tible to bacterial infection.
Interestingly, the lysozyme membrane eluate contained
0.43 ± 0.07 mg/mL protein content and caused 51% bacterial in-
hibition, whereas purified lysozyme of a similar protein concentration
(0.5 mg/mL) almost completely abolished S. ratti growth over the same
time period (p < 0.0001, Fig. 8). To investigate the cause of this ap-
parent reduction in activity, samples of placebo membranes were eluted
in 0.5 mg/mL lysozyme solution. The resulting eluate inhibited growth
Fig. 6. Cumulative release of lysozyme from membranes electrospun using 97
v/v % ethanol as a solvent following immersion in PBS. Data is presented as
mean ± SD, with 3 independent samples for each time point.
Fig. 7. SEM micrographs of the continuous PCL backing layer film formed after thermal treatment (A) and the edge of the patch showing the PCL film backing layer
and lower layer of lysozyme-containing PVP and RS100 fibres (B). Activity of lysozyme released from patches with PCL backing layers before and after melting at
65 °C for 15 min (C). Data is presented as mean ± SD, with 3 independent samples, and analysed using Welch's t-test.
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to the same extent as the lysozyme membrane eluent, suggesting that
this disparity related to polymer in the sample and not loss of activity
during electrospinning. This may be a result of water soluble PVP
leaching from the fibres and inhibiting lysozyme activity or en-
capsulating and protecting the bacteria. PVP has previously been shown
to inhibit the enzyme phenolase [42], however its effect on lysozyme
has not been studied. Further investigation would be required to elu-
cidate the mechanism of this effect.
4. Conclusions
This mucoadhesive system enabled the encapsulation of an enzyme
into polymer fibres with superior encapsulation efficiency and biolo-
gical activity preservation compared to what has previously been ac-
complished with uniaxial electrospinning. The approach described here
is considerably simpler to scale up to an industrial manufacturing set-
ting than the frequently reported emulsion and coaxial electrospinning
techniques, with fewer parameter to optimise and control. Unlike pre-
vious systems, the fibres released the majority of the protein in a single
burst at a rate appropriate for drug delivery to the oral mucosa.
Furthermore, the protein was homogenously distributed, and data
suggest that the dual-layer patches maintained mucoadhesive proper-
ties similar to those previously reported [14]. The biological activity of
the encapsulated protein was further demonstrated by the inhibition of
growth of an oral bacterial strain. This illustrates that the patches could
be useful for the local delivery of antimicrobial proteins. In practise,
there are likely to be many more suitable candidate protein drugs, since
lysozyme is only active against specific bacterial strains [41]. For ex-
ample, patches loaded with the antifungal peptide histatin-5 may be
effective against chlorhexidine resistant periodontal Candida biofilms
[43]. The food-grade preservative nisin has broad spectrum activity
against many Gram-positive bacteria, and could potentially be in-
corporated into the patches to treat multi-species bacterial biofilms
[44]. The patch technology reported here holds great promise as a
novel therapeutic protein delivery system for the oral mucosa.
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